The Endpoints 100 gives a C-suite thumbs down on ‘crippling’ price proposals and Aduhelm. Plus: Is anyone going to JP Morgan?

After tracking the opinion of the Endpoints 100 — biotech execs, mostly CEOs, who give us semi-annual feedback on key issues and trends — for the past four years, one thing stands out: Opinions tend to run along lines of consensus; by and large they track as a pack.


Click to view original post